TAK

Takeda Pharmaceutical Co ADR

20.24

Oct 23 • 3:59 PM ET -0.12 (-0.59%)

20.24

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Drug Manufacturers - Specialty & Generic Japan Large NYSE

Oct 23, 8:06 AMTakeda Phase 3 G-HOPE-001 trial of TAK-921 meets dual primary endpoints in CLDN18.2-positive advanced gastric cancer

Peers: SNY GSK BMY AZN PFE ABBV NVS JNJ MRK GRFS

| Held by: FVD PPH AVDE APIE VEU BDYN JSTC BFLX GINX AVSD

Scroll to Statements

Index	-
Market Cap	64.41B
Enterprise Value	91.98B
Income	-1.05B
Sales	29.91B
Book/sh	14.71
Cash/sh	0.89
Dividend Est.	0.64 (3.18%)
Dividend TTM	0.63 (3.10%)
Dividend Ex-Date	Mar 31, 2026
Dividend Gr. 3/5Y	1.18% -5.75%
Payout	-
Employees	47029
IPO	Mar 06, 2008

P/E	-
Forward P/E	32.24
PEG	1.24
P/S	2.15
P/B	1.38
P/C	22.71
P/FCF	14.77
EV/EBITDA	9.93
EV/Sales	3.07
Quick Ratio	0.62
Current Ratio	1.14
Debt/Eq	0.65
LT Debt/Eq	0.58
Option/Short	Yes / Yes

EPS (ttm)	-0.34
EPS next Y	0.63
EPS next Q	0.14
EPS this Y	1.73%
EPS next Y	60.32%
EPS next 5Y	25.97%
EPS past 3/5Y	- -
Sales past 3/5Y	0.19% -0.17%
EPS Y/Y TTM	-208.74%
Sales Y/Y TTM	-0.14%
EPS Q/Q	-18.22%
Sales Q/Q	0.00%
Earnings	Jul 30 AMC
EPS/Sales Surpr.	33.21% 7.40%

Insider Own	0.00%
Insider Trans	-
Inst Own	3.30%
Inst Trans	0.24%
ROA	-1.08%
ROE	-2.22%
ROIC	-1.42%
Gross Margin	54.53%
Oper. Margin	15.28%
Profit Margin	-3.49%
SMA20	6.98%
SMA50	8.85%
SMA200	16.00%
Trades

Shs Outstand	3.18B
Shs Float	3.18B
Short Float	0.09%
Short Ratio	1.02
Short Interest	2.92M
52W High	20.39 -0.74%
52W Low	12.99 55.81%
Volatility	1.21% 1.38%
ATR (14)	0.34
RSI (14)	70.35
Beta	0.02
Rel Volume	0.74
Avg Volume	2.85M
Volume	2,099,266

Perf Week	2.90%
Perf Month	8.88%
Perf Quarter	16.06%
Perf Half Y	21.71%
Perf YTD	29.83%
Perf Year	43.95%
Perf 3Y	39.39%
Perf 5Y	43.85%
Perf 10Y	-11.34%
Recom	1.94
Target Price	20.80
Prev Close	20.36
Price	20.24
Change %	-0.59%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-08-26	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-13-26	Resumed	Morgan Stanley	Overweight
Apr-02-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Mar-16-23	Upgrade	BofA Securities	Neutral → Buy	$20
Jul-19-22	Upgrade	Cowen	Market Perform → Outperform	$21 → $24
Oct-07-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-19-21	Downgrade	JP Morgan	Overweight → Neutral
Nov-01-19	Initiated	Cowen	Market Perform	$19.50
Aug-15-19	Downgrade	Daiwa Securities	Outperform → Neutral

Oct-23-26 07:30AM	Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study (Business Wire)
Oct-20-26 06:03PM	Stephen K. Brannan, MD, and John D. Young Appointed to Slate Medicines Board of Directors (Exec Edge)
Oct-19-26 09:59AM	Merck KGaA bets on RNAi with $1.3B Silence buyout (BioPharma Dive)
05:30AM	First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO (vedolizumab) Prolongs Time to First Disease-Related Complication (Business Wire)
Oct-15-26 01:38PM	Cathie Wood-Backed Biotech IPO Pops in Debut (Barrons.com)
08:30PM	Loading…
Oct-14-26 08:30PM	Takedas ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1 (Business Wire)
Oct-11-26 09:22PM	SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH (Stocktwits)
Sep-30-26 01:00AM	Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill (Business Wire)
Sep-25-26 08:57AM	Basecamp raises $140M before the clinic; J&J and Compass potential rivalry (Pharma Voice)
Sep-22-26 09:30AM	Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026 (Business Wire)
Sep-18-26 01:00AM	Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems (Business Wire)
Sep-14-26 03:00AM	U.S. FDA Accepts New Drug Application Under Priority Review for Takedas Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations (Business Wire)
Sep-10-26 07:24AM	Andy Plump, architect of Takedas R&D overhaul, to retire next year (BioPharma Dive)
Sep-09-26 08:24AM	New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life (Business Wire)
Sep-02-26 05:50AM	Takeda and Weave Bio collaborate on AI-driven automation in drug development (Pharmaceutical Technology)
06:08PM	Loading…
Aug-31-26 06:08PM	Chris Benecchi Named Inventivas New Chief Operating Officer (Exec Edge)
08:13AM	FDA OKs Takeda, Protagonist drug for rare blood cancer (BioPharma Dive)
Aug-28-26 06:40PM	Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera (Business Wire)
06:34PM	NVAX Stock Climbs As Partnership Model Keeps COVID Vaccine Cash Flow Open (Stocktwits)
Aug-24-26 02:36AM	ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 (Business Wire)
Aug-12-26 05:11AM	Silence cashes in on differentiated data; UK reaffirms support for childhood vaccines (BioPharma Dive)
Aug-10-26 09:26AM	Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline (NYSE)
Aug-06-26 10:11AM	Takeda nets first-in-class advantage on narcolepsy drugs FDA go-ahead (Pharmaceutical Technology)
08:08AM	Takeda approval ushers in new wave of sleep drugs (BioPharma Dive)
01:04AM	Exelixis Inc (EXEL) (Q2 2026) Earnings Call Highlights: Strong Cabozantinib Growth Offsets NET ... (GuruFocus.com)
Aug-05-26 06:10PM	U.S. FDA Approves Takedas ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 (Business Wire)
Jul-30-26 02:37AM	Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track (Business Wire)
Jul-16-26 06:32PM	Change in Siegfried's Management Team (NewMediaWire)
06:00PM	Takedas Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies (Business Wire)
Jul-13-26 06:13AM	Takeda and Indonesia partner on plasma-derived therapies (Pharmaceutical Technology)
04:20AM	Loading…
04:20AM	Moderna, Takeda and Capricor on the verge of notching big drug approvals (Pharma Voice)
Jul-12-26 07:00PM	Takeda and the Indonesian Government Announce Landmark Collaboration to Strengthen Healthcare Resilience and Expand Access to Lifesaving Plasma-Derived Medicinal Products (Business Wire)
Jul-02-26 06:32AM	Insilico Medicine, Takeda partner on AI-driven drug discovery (Pharmaceutical Technology) +5.14%
Jun-26-26 05:46AM	Alkermes incoming CEO has a plan to outplay Lilly and Takeda (BioPharma Dive)
Jun-24-26 03:05AM	Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO (Business Wire)
Jun-15-26 12:00PM	New Pivotal Study Data Show Takedas Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 1 (Business Wire)
Jun-11-26 03:00AM	Takedas $4B TYK2 drug tops Bristol Myers Sotyktu in head-to-head test (BioPharma Dive)
Jun-09-26 04:30PM	U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease (Business Wire)
Jun-05-26 04:55AM	GSK, Takeda and others notch key clinical wins in tough-to-treat diseases (Pharma Voice)
Jun-04-26 05:22AM	Otsuka showcases kidney drug data; Pfizer cuts an AI deal (BioPharma Dive)
May-20-26 07:15AM	Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict (Pharmaceutical Technology)
06:43AM	Immunovants potential autoimmune blockbuster; Waves RNA editing update (BioPharma Dive)
May-18-26 05:51PM	Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda (Business Wire)
May-15-26 07:36AM	Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers (BioPharma Dive)
May-13-26 02:38AM	Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results (Business Wire)
May-04-26 08:00AM	Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID) (Business Wire)
Apr-14-26 08:02PM	Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now? (Quartz)
Apr-06-26 07:07AM	FDA floats new clinical trial reforms; Takeda punts Denali brain drug (BioPharma Dive)
Mar-28-26 03:00PM	Takedas Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care (Business Wire)
Mar-08-26 04:49PM	These 8 drugs could help fight dementia - and they're already on the market (MarketWatch)
12:01PM	FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment (Insider Monkey)
Mar-02-26 02:00AM	Takeda and Protagonist Announce U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Rusfertide as a Potential First-in-Class Therapy for Polycythemia Vera (Business Wire)
Feb-28-26 12:35PM	Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference (MarketBeat)
Feb-27-26 09:02AM	DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus (Zacks)
Feb-24-26 09:35AM	Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity (PR Newswire)
Feb-23-26 07:39AM	Novo Nordisk flags board members for re-election amid restructuring efforts (Pharmaceutical Technology)
Feb-20-26 10:17AM	Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps (Benzinga)
Feb-19-26 12:00PM	Positive Phase 3 Data Demonstrate Potential for ENTYVIO (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis (Business Wire)
Feb-18-26 10:10AM	FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer (Benzinga)
09:39AM	Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? (Zacks)
Feb-11-26 04:33AM	Evommune rockets on eczema data; AstraZeneca advances GLP-1 pill (BioPharma Dive)
Feb-10-26 08:30AM	Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market (PR Newswire)
05:30AM	Takeda and Iambic announce $1.7bn deal to advance small molecule programmes (Pharmaceutical Technology)
03:15AM	U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takedas Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1 (Business Wire)
Feb-09-26 12:59PM	Takeda Taps AI Startup Iambic In $1.7 Billion+ Deal To Speed Up Drug Discovery (Benzinga)
08:07AM	Takeda deepens AI drug discovery push with $1.7 billion Iambic deal (Reuters)
03:00AM	Takeda, Iambic partner in latest pharma AI push (BioPharma Dive)
Jan-31-26 09:36AM	Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? (Insider Monkey)
Jan-29-26 09:11AM	Takeda Flags Vyvanse Hit, Lifts 2025 Profit Guidance On Cost Control (Benzinga)
08:37AM	Takeda Pharmaceutical Q3 Earnings Call Highlights (MarketBeat)
01:37AM	Takeda Reports Third-Quarter FY2025 Results: Updates Full Year Outlook to Reflect VYVANSE Generics Impact, OPEX Discipline and FX Tailwind; Progressing Toward Three Transformative Launches Ahead (Business Wire)
Jan-28-26 07:48AM	CMS selects next batch of 15 high-cost medicines for third negotiation cycle (Pharmaceutical Technology)
05:51AM	Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle (Benzinga)
Jan-22-26 09:13AM	ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? (Zacks)
07:45AM	Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1 (Business Wire)
Jan-15-26 06:19PM	JPM26: Matrix-M Technology is central to Novavaxs strategy (Pharmaceutical Technology)
09:14AM	KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? (Zacks)
Jan-14-26 12:10AM	Ascentage: Partnership With Takeda Going Well (Bloomberg)
Jan-07-26 01:01PM	Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up (Zacks)
Jan-06-26 07:05AM	Takeda and Protagonist seek FDA approval for rusfertide to treat PV (Pharmaceutical Technology)
06:50AM	Alumis soars as TYK2 drug hits mark in psoriasis trials (BioPharma Dive)
Jan-05-26 07:00AM	Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) (Business Wire)
Dec-19-25 07:00AM	Cambridge property takes novel approach to quality in life sciences sector (Facilities Dive)
Dec-18-25 04:45AM	Takeda says $4B TYK2 drug succeeds in large psoriasis studies (BioPharma Dive)
03:00AM	Takedas Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment (Business Wire)
Dec-06-25 09:30AM	Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera (Business Wire)
Dec-05-25 09:56AM	Denali Enters Into a $275M Funding Deal With Royalty Pharma (Zacks)
05:19AM	Takeda and Innovent fulfil close conditions for ADC and IO therapies (Pharmaceutical Technology)
Nov-07-25 01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
Nov-03-25 07:00AM	New Phase 3 Data Show Takedas Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization (Business Wire)
Oct-30-25 03:04AM	Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year (Business Wire)
Oct-22-25 06:33AM	Chinas Innovent Strikes Cancer Drug Deal With Takeda for Up to $11.4 Billion (The Wall Street Journal)
Oct-21-25 05:53AM	Takeda Pharmaceutical Company (TAK) Signs a Research Partnership with Nabla Bio (Insider Monkey)
Oct-10-25 11:13AM	Johnson & Johnson in Talks to Buy Protagonist Therapeutics (The Wall Street Journal)
Sep-23-25 06:04PM	20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries (Business Wire)
Sep-17-25 05:45AM	5 Best High-Yield Dividend Stocks to Buy Now (Motley Fool)
Sep-16-25 08:00AM	Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran (Business Wire)
Sep-08-25 03:00AM	Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 (Business Wire)
Sep-05-25 08:45PM	U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease (Business Wire)
Aug-28-25 04:55AM	Takeda Pharmaceutical Company Limited (TAK) Advances ?d T Cell Cancer Treatments (Insider Monkey)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Duprey Lauren Rusckowski	Chief Transformation Officer	Sep 14 '26	Sale	18.54	34,535	640,279	191,522	Sep 15 09:12 PM
Lauren Rusckowski Duprey	Chief Transformation Officer	Sep 10 '26	Proposed Sale	18.37	34,535	634,408		Sep 10 08:00 AM
Plump Andrew Stewart	President, R&D	Sep 02 '26	Sale	18.49	116,191	2,148,372	145,465	Sep 03 09:49 PM
Plump Andrew Stewart	Officer	Sep 02 '26	Proposed Sale	18.49	116,191	2,148,372		Sep 02 04:14 PM
Plump Andrew Stewart	President, R&D	Aug 19 '26	Sale	18.49	19,651	363,347	261,656	Aug 21 04:30 PM
Greenway Nicola Deidre Petal	Chief Human Resources Officer	Aug 18 '26	Sale	18.11	12,980	235,118	40,049	Aug 19 04:15 PM
Plump Andrew Stewart	Officer	Aug 19 '26	Proposed Sale	18.49	19,651	363,348		Aug 19 03:58 PM
Nicola Greenway	Chief Human Resources Officer	Aug 14 '26	Proposed Sale	17.39	12,980	225,722		Aug 14 04:10 PM
Farajallah Awny Samaan Botros	Chief Medical Officer	Aug 10 '26	Sale	17.10	14,006	239,503	116,177	Aug 12 09:54 PM
Ibrahim Ramy Riad Ahmed	President, PDT BU	Aug 10 '26	Sale	17.10	7,277	124,437	102,588	Aug 12 09:53 PM
Pacheco Rhonda Janice	President, U.S. Business Unit	Aug 10 '26	Sale	17.10	16,901	289,007	182,507	Aug 12 09:53 PM
Duprey Lauren Rusckowski	Chief Transformation Officer	Aug 10 '26	Sale	17.10	47,586	813,721	226,057	Aug 12 09:51 PM
Plump Andrew Stewart	President, R&D	Aug 10 '26	Sale	17.10	165,393	2,828,220	766,569	Aug 12 09:50 PM
Pignagnoli Agosti Marcello	Head, Strat. & Port. Dev	Aug 10 '26	Sale	17.10	22,957	392,565	176,977	Aug 12 09:46 PM
Bitetti Teresa Marie	President, OBU	Aug 10 '26	Sale	17.10	50,012	855,205	252,010	Aug 12 09:45 PM
Shannon Elaine Mary	Pres., Global Supply & Quality	Aug 10 '26	Sale	17.10	3,978	68,024	63,333	Aug 12 09:42 PM
Ricci Gabriele	Chief Data & Tech. Officer	Aug 10 '26	Sale	17.10	25,088	429,005	171,654	Aug 12 09:39 PM
Greenway Nicola Deidre Petal	Chief Human Resources Officer	Aug 10 '26	Sale	17.10	6,774	115,835	53,029	Aug 12 09:28 PM
Kim Julie So-Young	President and CEO	Aug 10 '26	Sale	17.10	89,090	1,523,439	391,489	Aug 12 09:27 PM
Platford Giles Richard	President, IBU	Aug 10 '26	Sale	17.10	31,083	531,519	315,838	Aug 12 09:25 PM
Furney Natalie Anne Marie	Global General Counsel	Aug 10 '26	Sale	17.10	30,868	527,843	204,298	Aug 12 09:23 PM
Shannon Elaine Mary	Pres., Global Supply & Quality	Aug 11 '26	Sale	17.55	20,363	357,371	67,311	Aug 12 04:10 PM
Greenway Nicola Deidre Petal	Chief Human Resources Officer	Aug 10 '26	Sale	17.51	34,603	605,778	59,803	Aug 12 04:10 PM
Elaine Shannon	President, Global Supply & Qua	Aug 11 '26	Proposed Sale	17.45	20,363	355,334		Aug 10 04:30 PM
Nicola Greenway	Chief Human Resources Officer	Aug 07 '26	Proposed Sale	16.72	34,603	578,562		Aug 06 05:17 PM
Marcello Pignagnoli Agosti	Interim Head, Strategy and Por	Jul 13 '26	Proposed Sale	16.75	24,887	416,850		Jul 13 06:26 AM
Lauren Rusckowski Duprey	Chief Transformation Officer	Jul 13 '26	Proposed Sale	16.75	51,579	863,947		Jul 13 06:26 AM
Giles Platford	President, International Busin	Jul 13 '26	Proposed Sale	16.75	33,696	564,406		Jul 13 06:25 AM
Natalie Furney	Global General Counsel	Jul 13 '26	Proposed Sale	16.75	33,454	560,351		Jul 13 06:25 AM
Gabriele Ricci	Chief Data & Technology Office	Jul 13 '26	Proposed Sale	16.75	27,197	455,545		Jul 13 06:24 AM
Nicola Greenway	Chief Human Resources Officer	Jul 13 '26	Proposed Sale	16.75	7,348	123,072		Jul 13 06:24 AM
Elaine Shannon	President, Global Supply & Qua	Jul 13 '26	Proposed Sale	16.75	4,319	72,351		Jul 13 06:23 AM
Ramy Riad	President, Plasma-Derived Ther	Jul 13 '26	Proposed Sale	16.75	7,889	132,149		Jul 13 06:23 AM
Awny Farajallah	Chief Medical Officer	Jul 13 '26	Proposed Sale	16.75	15,188	254,399		Jul 13 06:22 AM
Rhonda Pacheco	President, US Business Unit an	Jul 13 '26	Proposed Sale	16.75	18,316	306,789		Jul 13 06:22 AM
Andrew Plump	President, Research & Developm	Jul 13 '26	Proposed Sale	16.75	179,239	3,002,258		Jul 13 06:21 AM
Teresa Bitetti	President, Global Oncology Bus	Jul 13 '26	Proposed Sale	16.75	54,210	908,019		Jul 13 06:21 AM
Julie Kim	President and CEO	Jul 13 '26	Proposed Sale	16.75	96,558	1,617,344		Jul 13 06:07 AM
Lauren Rusckowski Duprey	Chief Human Resources Officer	Dec 09 '25	Proposed Sale	14.22	29,619	421,182		Dec 09 06:05 AM
Teresa Marie Bitetti	President, Global Oncology Bus	Dec 05 '25	Proposed Sale	14.28	87,023	1,242,688		Dec 05 06:08 AM
Giles Richard Platford	President, Plasma-Derived Ther	Dec 04 '25	Proposed Sale	14.31	58,421	836,005		Dec 04 06:02 AM

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

CFO & DirectorMr. Milano Furuta

Ph.D.Dr. Andrew S. Plump M.D.

CEOMs. Julie Kim

Chair of Management BoardDr. Seigo Izumo

Member of Management BoardMr. Haruhiko Hirate

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TAK

Takeda Pharmaceutical Co ADR

Upgrade your Finviz experience